We are thrilled to be attending DPHARM 2025: Disruptive Innovations in Philadelphia (Sept 16-17) — to engage with our peers and showcase how our unique technology makes trials safer, more reliable, and more cost-effective.
Why Duplicate Subjects and Professional Patients Are a Serious Risk
One of the most persistent challenges in clinical research today is the enrollment of duplicate subjects and professional patients — individuals who conceal or misrepresent their study history to qualify for multiple trials. These behaviors can lead to:
- Compromised subject safety from overlapping exposures
- Distorted efficacy outcomes
- Elevated placebo response rates
- Regulatory non-compliance
- Increased trial costs and, in some cases, outright trial failure
What VCT Brings to the Table
Verified Clinical Trials (VCT) is the only solution that can look into a research subject’s past clinical trial history and detect duplicates or professional patients at the time of screening — and continue protection for the entire duration of the study.
- Screening-time detection: Our registry flags duplicate subjects before they are randomized.
- Continuous protection: Even after enrollment, our technology prevents subjects from attempting to participate in additional studies simultaneously.
- Comprehensive audit trails: Ensuring compliance and providing transparency for sponsors, CROs, and regulators.
- Outstanding ROI:
• Reduced wasted screening costs and staff time
• Fewer protocol violations and deviations
• Mitigation of risks that could cause trial failure
What You’ll Learn from Us at DPHARM
At DPHARM, we will highlight:
- Case studies demonstrating how VCT prevented duplicate subjects and professional patients from jeopardizing study integrity
- Integration pathways for sites, CROs, and sponsors to adopt duplicate protection without disrupting workflow
- Real metrics showing savings in time, cost, and resources
Why It Matters
- Sponsors safeguard their investments and improve trial outcomes.
- Sites & Investigators reduce the burden of screening professional patients and ensure subject safety.
- Regulators & Ethics Committees gain confidence that participant protection and data quality are prioritized.
See You at DPHARM
We look forward to seeing our valued clients and friends in Philadelphia — and to building new relationships with those eager to strengthen their trials against the risks of duplicate subjects and professional patients.
Together, we can ensure safer research, stronger data, and more successful clinical trials.